Literature DB >> 27187863

Conjugation of weak ligands with weak antigens to activate TLR-7: A step toward better vaccine adjuvants.

Dong Gao1, Juan Zeng2, Xiaodong Wang3, Yu Liu4, Wang Li3, Yunlong Hu3, Ningning Gao3, Yuwen Diao3, Zhulin Wang3, Wenqi Jiang3, Jinhua Chen5, Guangyi Jin6.   

Abstract

To study the structure-activity relationship (SAR) of Toll-like receptor 7 (TLR-7) agonists based on 8-oxoadenines, a novel subset of C9-substituted 8-hydroxy-2-(2-methoxyethoxy)-adenines and their antigen conjugates were synthesized. In vitro, the ability of cytokines (IL-12p70 and IFN-γ) induction of ligands with alkyl acid at C9-position were very weak compared with benzoic acid counter parts. Unexpectedly, its antigen conjugates that conjugated with proteins or peptides with weak immunogenicity, showed enhanced activity of cytokines induction. After administered systemically in mice in vivo, all conjugates induced prolonged increase in pro-inflammatory cytokines and antigen-specific IgG levels in serum compared with free compounds. Results from molecular dynamics (MD) simulations further confirmed the conclusion and provided the details of interaction to explain the phenomenon of experiment. In conclusion, we discovered that TLR-7 could be activated via some conjugates of weak ligand and weak antigen, which could be safer adjuvant candidates for vaccines in the future.
Copyright © 2016 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adenine derivative; Adjuvant; Immunostimulatory activity; Toll-like receptor

Mesh:

Substances:

Year:  2016        PMID: 27187863     DOI: 10.1016/j.ejmech.2016.04.070

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series.

Authors:  Jay T Evans; Laura S Bess; Sandra C Mwakwari; Mark T Livesay; Yufeng Li; Van Cybulski; David A Johnson; Hélène G Bazin
Journal:  ACS Omega       Date:  2019-09-10

2.  Multifunctional Protein Conjugates with Built-in Adjuvant (Adjuvant-Protein-Antigen) as Cancer Vaccines Boost Potent Immune Responses.

Authors:  Jing-Jing Du; Chang-Wei Wang; Wen-Bo Xu; Lian Zhang; Yuan-Kai Tang; Shi-Hao Zhou; Xiao-Fei Gao; Guang-Fu Yang; Jun Guo
Journal:  iScience       Date:  2020-02-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.